Program
cabozantinib
Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.
Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.
Drug pageCabozantinib: every studyMany companies study it; this page follows only the 33 they lead. All 223 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixisits history only | 237 open or running | phase 4since Jul 8, 2013 | Sep 20, 2005 | May 31, 2030phase 3 · NCT07620574 |
| Bristol-Myers Squibbits history only | 51 open or running | phase 3since May 3, 2017 | Nov 24, 2009 | Aug 25, 2029phase 2 · NCT03899155 |
| Ipsenits history only | 20 open or running | phase 2since May 9, 2019 | May 9, 2019 | none ahead |
| Takedaits history only | 20 open or running | phase 2since Nov 8, 2017 | Nov 8, 2017 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Apr 23, 2018 | Apr 23, 2018 | none ahead |
Also a collaborator on its studies: Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Roche-Genentech and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Sep 20, 2005.
- May 3, 2017Phase 3 study in Carcinoma, Renal CellBristol-Myers Squibb · NCT03141177 · 701 enrolled · United States, Argentina, Australia and more
- May 23, 2017Phase 1 study in Carcinoma, Transitional CellExelixis · NCT03170960 · 914 enrolled · United States, Australia, Belgium and more
- Nov 8, 2017Takeda’s first study: phase 2 study in Advanced Renal Cell CarcinomaNew to TakedaTakeda · NCT03339219 · 35 enrolled · Japan
- Apr 23, 2018Academic Thoracic Oncology Medical Investigators Consortium’s first study: phase 2 study in Colorectal NeoplasmsNew to Academic Thoracic Oncology Medical Investigators ConsortiumAcademic Thoracic Oncology Medical Investigators Consortium · NCT03542877 · 44 enrolled · United States
- Jun 29, 2018Phase 2 study in Advanced Hepatocellular CarcinomaTakeda · NCT03586973 · 34 enrolled · Japan
- Sep 26, 2018Phase 3 study in Thyroid Cancer, PapillaryExelixis · NCT03690388 · 187 enrolled · United States, Argentina, Australia and more
- Nov 26, 2018Phase 3 study in Carcinoma, HepatocellularExelixis · NCT03755791 · 837 enrolled · United States, Argentina, Australia and more
- Apr 1, 2019Phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155 · 1,500 planned · United States, Argentina, Australia and more
- May 2, 2019Phase 3 study in Carcinoma, Renal CellExelixis · NCT03937219 · 855 enrolled · United States, Argentina, Australia and more
- May 9, 2019Ipsen’s first study: phase 2 study in Carcinoma, Renal CellNew to IpsenIpsen · NCT03945773 · 127 enrolled · Austria, France, Germany and more
- Nov 1, 2019Phase 2 study in CarcinomaBristol-Myers Squibb · NCT04151563 · United States, Argentina, Belgium and more
- Jun 22, 2020Phase 3 study in Prostatic NeoplasmsExelixis · NCT04446117 · 575 enrolled · United States, Argentina, Australia and more
- Mar 4, 2024Phase 2 study in OsteosarcomaIpsen · NCT06341712 · 10 enrolled · United States, Belgium, Canada and more
- May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States
Ahead
- Aug 25, 2029Primary completion: phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155
- May 31, 2030Primary completion: phase 3 study in NeoplasmsExelixis · NCT07620574
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07620574Neoplasms · United States | 3 | By invitation | Exelixis | May 31, 2030 | 5,000 |
| NCT06341712Osteosarcoma · United States, Belgium, Canada and more | 2 | Terminated | Ipsen | Feb 27, 2026 | 10 |
| NCT04446117Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Apr 19, 2024 | 575 |
| NCT04151563Carcinoma · United States, Argentina, Belgium and more | 2 | Withdrawn | Bristol-Myers Squibb | Dec 17, 2023 | 0 |
| NCT03945773Carcinoma, Renal Cell · Austria, France, Germany and more | 2 | Completed | Ipsen | May 11, 2023 | 127 |
| NCT03937219Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Jan 31, 2022 | 855 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Aug 25, 2029 | 1,500 |
| NCT03755791Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Nov 30, 2021 | 837 |
| NCT03690388Thyroid Cancer, Papillary · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Aug 19, 2020 | 187 |
| NCT03586973Advanced Hepatocellular Carcinoma · Japan | 2 | Completed | Takeda | Jul 17, 2019 | 34 |
| NCT03542877Colorectal Neoplasms · United States | 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | Oct 19, 2020 | 44 |
| NCT03339219Advanced Renal Cell Carcinoma · Japan | 2 | Completed | Takeda | Aug 25, 2020 | 35 |
| NCT03170960Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 1 | Active, not recruiting | Exelixis | Feb 21, 2023 | 914 |
| NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 12, 2020 | 701 |
| NCT01995058Prostatic Neoplasms · United States | 2 | Terminated | Exelixis | Nov 2014 | 54 |
| NCT01908426Carcinoma, Hepatocellular · United States, Australia, Belgium and more | 3 | Completed | Exelixis | Oct 16, 2017 | 707 |
| NCT01896479Carcinoma, Medullary · Australia, Canada, Croatia and more | 4 | Active, not recruiting | Exelixis | Jul 15, 2020 | 247 |
| NCT01865747Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Exelixis | May 22, 2015 | 658 |
| NCT01761773Renal Insufficiency · United States | 1 | Completed | Exelixis | Apr 2013 | 32 |
| NCT01658878Carcinoma, Hepatocellular · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2024 | 657 |
| NCT01605227Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Exelixis | Sep 2014 | 1,028 |
| NCT01553656Neoplasms · Japan | 1 | Completed | Exelixis | May 2015 | 85 |
| NCT01522443Prostatic Neoplasms · United States, Australia, Canada and more | 3 | Terminated | Exelixis | Oct 2014 | 119 |
| NCT01493869Healthy · United States | 1 | Completed | Exelixis | May 2014 | 26 |
| NCT01100619Thyroid Cancer, Papillary · United States | 1 | Completed | Exelixis | Aug 2012 | 40 |
| NCT01068782Glioblastoma · United States, Canada | 2 | Terminated | Exelixis | May 2011 | 19 |
| NCT01018745Neoplasms · Japan | 1 | Completed | Bristol-Myers Squibb | Jul 2010 | 3 |
| NCT00960492Glioblastoma · United States | 1 | Completed | Exelixis | Nov 2012 | 26 |
| NCT00940225Neoplasms · United States, Belgium, Israel and more | 2 | Completed | Exelixis | May 2013 | 730 |
| NCT00704730Thyroid Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Exelixis | Oct 2011 | 330 |
| NCT00704288Glioblastoma · United States | 2 | Completed | Exelixis | Jun 2012 | 222 |
| NCT00596648Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Exelixis | Aug 2, 2012 | 92 |
| NCT00215605Lymphoma · United States | 1 | Completed | Exelixis | Apr 2011 | 85 |
How it is read
Names in the registry
- “Cabozantinib”, 18 entries
- “cabozantinib”, 9 entries
- “XL184”, 6 entries
- “Cabozantinib tablets”, 2 entries
- “Cabozantinib (XL184) 140 mg”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 6 studies
- Carcinoma, Renal Cell, 5 studies
- Prostatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 4 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.